The high prices of weight-loss and diabetes drugs like Ozempic may soon be a focus of Medicare drug price negotiations. List prices for these drugs are between $936 and $1,349 per month. The Inflation Reduction Act signed by President Biden allows for direct negotiation of drug prices with manufacturers for the first time. Medicare spent $5.7 billion on GLP-1 drugs in 2022, up significantly from previous years. The negotiations could impact prices for all patients, not just Medicare beneficiaries. The future of drug pricing negotiations may also depend on the outcome of the next election.
Source link
Weight-Loss Drugs Are So Popular They’re Headed for Medicare Negotiations
